Gene therapy for primary immunodeficiencies
- PMID: 20493399
- DOI: 10.1016/j.iac.2010.02.002
Gene therapy for primary immunodeficiencies
Erratum in
- Immunol Allergy Clin North Am. 2011 May;31(2): I. Cavazanna-Calvo, M [corrected to Cavazzana-Calvo, M]
Abstract
The concept of gene therapy emerged as a way of correcting monogenic inherited diseases by introducing a normal copy of the mutated gene into at least some of the patients' cells. Although this concept has turned out to be quite complicated to implement, it is in the field of primary immunodeficiencies (PIDs) that proof of feasibility has been undoubtedly achieved. There is now a strong rationale in support of gene therapy for at least some PIDs, as discussed in this article.
Copyright (c) 2010 Elsevier Inc. All rights reserved.
Republished in
-
Gene therapy for primary immunodeficiencies.Hematol Oncol Clin North Am. 2011 Feb;25(1):89-100. doi: 10.1016/j.hoc.2010.11.007. Hematol Oncol Clin North Am. 2011. PMID: 21236392
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical